Imprivata

Imprivata is a digital identity and access security company headquartered in Waltham, Massachusetts. Its business is concentrated primarily in healthcare, where clinicians, staff, contractors, and other users must reach many clinical and administrative systems while maintaining strong controls over authentication, authorization, privacy, and auditability. The company’s portfolio addresses this tension by combining single sign-on, multifactor and alternative authentication, identity governance, privileged access management, mobile-device access, and monitoring of access to sensitive patient information. The company was founded by David Ting and Phil Scarfo, who had worked on identity-management technology through a small-business incubator associated with Polaroid Corporation. Imprivata’s first commercial product was the OneSign Enterprise Single Sign-on appliance, which shipped in 2004. OneSign was designed to reduce the operational burden of repeated passwords and application logins while supporting stronger authentication methods. Its capabilities included access to enterprise applications without requiring extensive changes to existing directories or custom scripting, together with authentication options such as biometrics, proximity cards, smart cards, government or national identity cards, one-time-password tokens, and location-based controls. Centralized authentication and access-event records also supported compliance reporting. Imprivata expanded beyond its initial United States base during the mid-2000s. The company expanded into Europe, Africa, and the Middle East in 2005, and by 2006 it had established a broader European presence. Its technology leadership received external recognition when co-founder David Ting was named by InfoWorld among its leading chief technology officers in 2006. By 2017, the company reported more than 1,700 customers and offices across North America, Europe, and Australia. Healthcare organizations remained its principal customer group. The company broadened its platform through acquisitions. In 2009, it acquired assets of IdentiPHI, including the SAFsolution biometric-technology product line. In 2011, it acquired assets of Validus Medical Systems, whose technology was incorporated into Imprivata Cortext. These transactions expanded the company’s authentication, biometric, and secure communication capabilities. In 2019, Imprivata acquired GroundControl to strengthen its mobile offerings. In 2020, it acquired FairWarning, adding technology associated with digital-identity protection and patient-privacy monitoring. It subsequently acquired Xton Technologies and SecureLink, extending its capabilities into privileged access management for both internal users and external parties. Imprivata became a public company on June 25, 2014, with its shares listed on the New York Stock Exchange. Its public-company period ended in 2016, when private-equity firm Thoma Bravo acquired the company. The transaction was announced at a price of $19.25 per share and was reported at an estimated total value of $544 million. Omar Hussain was chief executive when the transaction was announced. Imprivata is now positioned as a specialized identity-security provider for complex, highly regulated environments, particularly healthcare, where secure access must coexist with clinical speed, shared workstations, mobile workflows, privacy obligations, and extensive third-party access.

Imprivata originated in identity-management work developed by David Ting and Phil Scarfo while they were associated with Polaroid Corporation’s small-business incubator. The founders established the company around the need to simplify secure access to enterprise applications without forcing organizations to redesign their existing application environments. Its first commercial product, the OneSign Enterprise Single Sign-on appliance, reached the market in 2004. OneSign provided a central mechanism for managing user authentication and application access. In addition to reducing repeated password entry, the system supported stronger authentication methods including fingerprint biometrics, proximity cards, smart cards, government and national identity cards, one-time-password tokens, and location-based authentication. Consolidated access records could also assist organizations with compliance reporting. These capabilities were particularly relevant to healthcare institutions, where staff often move among shared workstations and numerous clinical systems under strict privacy and security requirements. Imprivata began international expansion in 2005, reaching Europe, Africa, and the Middle East, and expanded its European presence further in 2006. In that year, co-founder David Ting was recognized by InfoWorld as one of its leading chief technology officers. By 2017, Imprivata had more than 1,700 customers and offices in the Americas, Europe, and Australia. Its customer base was primarily made up of healthcare organizations. The company used acquisitions to broaden its identity and access portfolio. In 2009, it acquired assets of IdentiPHI, a biometric-technology manufacturer and reseller, including the SAFsolution line. In 2011, it acquired assets of Validus Medical Systems of Santa Cruz, California; those assets were incorporated into Imprivata Cortext. The company later pursued mobile, privacy, and privileged-access opportunities. GroundControl was acquired in 2019 to expand mobile capabilities, while FairWarning was acquired in 2020 to strengthen the company’s digital-identity and patient-privacy offering. Acquisitions of Xton Technologies and SecureLink subsequently extended the platform into privileged access management for internal employees, vendors, contractors, and other external users. Imprivata entered the public markets on June 25, 2014, when it became listed on the New York Stock Exchange. The public-company phase ended in 2016 after Thoma Bravo agreed to acquire the business. The announced consideration was $19.25 per share, with an estimated transaction value of $544 million. Omar Hussain was chief executive at the time. Under private ownership, Imprivata continued to be described as a digital identity security company with a strong healthcare orientation. Its overall development reflects a progression from enterprise single sign-on and authentication toward a broader platform covering identity governance, mobile access, privacy monitoring, and privileged access management.

1. 2020FairWarning acquisition

   FairWarning was acquired to broaden Imprivata’s digital-identity and patient-privacy capabilities.

   Source
2. 2019GroundControl acquisition

   GroundControl was acquired to expand Imprivata’s mobile offerings.

   Source
3. 2016Acquired by Thoma Bravo

   Thoma Bravo agreed to take Imprivata private in a transaction valued at an estimated $544 million.

   Source
4. 2014New York Stock Exchange listing

   Imprivata became a public company on June 25, 2014.

   Source
5. 2011Validus Medical Systems assets acquired

   Assets of Validus Medical Systems were acquired and incorporated into Imprivata Cortext.

   Source
6. 2009IdentiPHI assets acquired

   Imprivata acquired IdentiPHI assets, including the SAFsolution biometric-technology product line.

   Source
7. 2006Technology leadership recognition

   Co-founder David Ting was selected by InfoWorld among its leading chief technology officers of the year.

   Source
8. 2005International expansion begins

   The company expanded into Europe, Africa, and the Middle East.

   Source
9. 2004First OneSign product reaches the market

   Imprivata shipped the OneSign Enterprise Single Sign-on appliance, its first commercial product.

   Source

A specialized digital identity and access security provider for healthcare and other regulated environments, emphasizing secure, fast, auditable access for clinical, administrative, mobile, privileged, and third-party users.

• Imprivata OneSignEnterprise single sign-on and authentication2004

  Imprivata’s first commercial product, OneSign is an enterprise single sign-on and authentication platform designed to simplify access to multiple applications. It can support existing directories and applications without requiring extensive custom scripting or application modification. Authentication options described for the product include fingerprint biometrics, proximity cards, smart cards, government or national identity cards, one-time-password tokens, and physical-location signals. Centralized access and authentication records can help organizations produce compliance reports and audit user activity.

• Imprivata Identity GovernanceIdentity governance

  Imprivata Identity Governance is positioned as part of the company’s broader digital-identity portfolio. It addresses the administration and oversight of user identities, permissions, and access relationships in regulated organizations. The offering is intended to complement authentication by helping organizations understand who has access to systems and whether that access remains appropriate. Specific current product packaging and feature details are not established in the supplied sources.

• Imprivata Patient Privacy MonitoringPatient privacy and access monitoring

  Imprivata Patient Privacy Monitoring addresses the oversight of access to patient information. It is associated with the company’s effort to help healthcare providers identify potentially inappropriate or anomalous access and support privacy obligations. The capability was strengthened by the acquisition of FairWarning in 2020, which expanded Imprivata’s digital-identity and monitoring platform.

• Imprivata CortextSecure healthcare communication

  Imprivata Cortext is a secure communication technology associated with the assets acquired from Validus Medical Systems in 2011. It forms part of Imprivata’s healthcare-oriented portfolio, supporting the company’s broader objective of enabling protected communication and access in clinical environments. The supplied reference material does not establish the full current product scope or launch details.

• GroundControl mobile offeringsMobile device and workflow management2019

  GroundControl’s capabilities became part of Imprivata’s portfolio after the 2019 acquisition. The transaction was intended to expand support for mobile devices and mobile workflows, an important requirement for healthcare personnel who access systems across shared clinical, bedside, and distributed environments. Detailed product names and current packaging are not specified in the supplied material.

• Xton and SecureLink privileged access capabilitiesPrivileged access management

  Imprivata expanded into privileged access management through acquisitions of Xton Technologies and SecureLink. These capabilities are intended to secure and govern elevated access for internal users as well as external parties such as vendors, contractors, and service providers. Their addition broadened Imprivata’s identity-security scope beyond ordinary workforce authentication to include high-risk administrative and third-party access.

• 2016Accept Thoma Bravo acquisition and leave public marketsM&A

  After becoming publicly listed in 2014, Imprivata received an acquisition proposal from private-equity firm Thoma Bravo. The company’s customer base and identity-security specialization made it a target for a private-equity ownership transition.

  What changed. Imprivata agreed to be acquired for $19.25 per share, at an estimated total transaction value of $544 million, ending its New York Stock Exchange listing.

  Aftermath. The transaction returned Imprivata to private ownership and allowed it to continue expanding its identity-security portfolio through later acquisitions.

  Announced acquisition value. $544 million estimated total transaction value (2016)

  Source

• 2020Imprivata acquires FairWarning

  The acquisition broadened Imprivata’s digital-identity platform with technology for monitoring access to sensitive information and supporting patient privacy.

  M&A
  Source
• 2019Imprivata acquires GroundControl

  The acquisition expanded Imprivata’s mobile-device and mobile-workflow capabilities.

  M&A
  Source
• 2016Thoma Bravo agrees to acquire Imprivata

  Private-equity firm Thoma Bravo agreed to acquire Imprivata for $19.25 per share, with the transaction reported at an estimated total value of $544 million.

  M&A
  Source
• 2014Imprivata becomes a public company on the New York Stock Exchange

  Imprivata completed its public-market listing on June 25, 2014.

  Other
  Source
• Imprivata expands privileged access management through Xton Technologies and SecureLink

  The company expanded into privileged access management for internal and external users through acquisitions of Xton Technologies and SecureLink.

  M&A
  Source

1. Imprivata